Corticosteroid use in neurocysticercosis

References

• Garcia HH, Del Brutto OH. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol.4(10), 653–661 (2005).
   PubMed Web of Science ®Google Scholar
• Flisser A. Taeniasis and cysticercosis due to Taenia solium. Prog. Clin. Parasitol.4, 77–116 (1994).
   PubMedGoogle Scholar
• Mahanty S, Garcia HH. Cysticercosis and neurocysticercosis as pathogens affecting the nervous system. Prog. Neurobiol.91(2), 172–184 (2010).
   PubMed Web of Science ®Google Scholar
• Lobato RD, Lamas E, Portillo JM et al. Hydrocephalus in cerebral cysticercosis. Pathogenic and therapeutic considerations. J. Neurosurg.55(5), 786–793 (1981).
   PubMed Web of Science ®Google Scholar
• Bickerstaff ER, Cloake PCP, Hughes B, Smith WT. The racemose form of cerebral cysticercosis. Brain75, 1–16 (1952).
   PubMed Web of Science ®Google Scholar
• Estanol B, Corona T, Abad P. A prognostic classification of cerebral cysticercosis: therapeutic implications. J. Neurol. Neurosurg. Psychiatry49(10), 1131–1134 (1986).
   PubMed Web of Science ®Google Scholar
• Nash TE, Singh G, White AC et al. Treatment of neurocysticercosis: current status and future research needs. Neurology67(7), 1120–1127 (2006).
   PubMed Web of Science ®Google Scholar
• Dumas JL, Vusy JM, Belin C. Parenchymal neurocysticercosis: follow up and staging by MRI. Neuroradiology39, 12–16 (1997).
   PubMed Web of Science ®Google Scholar
• Garcia HH, Del Brutto OH. Imaging findings in neurocysticercosis. Acta Tropica87, 71–78 (2003).
   PubMed Web of Science ®Google Scholar
• Nash TE, Del Brutto OH, Butman JA et al. Calcific neurocysticercosis and epileptogenesis. Neurology62(11), 1934–1938 (2004).
   PubMed Web of Science ®Google Scholar
• Sheth TN, Pillon L, Keystone J, Kucharczyk W. Persistent MR contrast enhancement of calcified neurocysticercosis lesions. AJNR Am. J. Neuroradiol.19(1), 79–82 (1998).
   PubMed Web of Science ®Google Scholar
• Ooi WW, Wijemanne S, Thomas CB, Quezado M, Brown CR, Nash TE. A calcified Taenia solium granuloma associated with recurrent perilesiona edema causing refractory seizures: histopathological features. Am. J. Trop. Med. Hyg. (2011) (In press).
   Google Scholar
• Nash TE, Pretell EJ, Lescano AG et al. Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study. Lancet Neurol.7(12), 1099–1105 (2008).
   PubMed Web of Science ®Google Scholar
• Nash TE, Pretell J, Garcia HH. Calcified cysticerci provoke perilesional edema and seizures. Clin. Infect. Dis.33(10), 1649–1653 (2001).
   PubMed Web of Science ®Google Scholar
• Henneberg R. [Parasites of the central nervous system]. In: Handbuch Der Neurologie. Lewandowsky M (Ed.). Verlag Von Julius Springer, Berlin, Germany, 643–712 (1912).
   Google Scholar
• Fleury A, Escobar A, Fragoso G, Sciutto E, Larralde C. Clinical heterogeneity of human neurocysticercosis results from complex interactions among parasite, host and environmental factors. Trans. R. Soc. Trop. Med. Hygiene104(4), 243–250 (2010).
   PubMed Web of Science ®Google Scholar
• De Melo CS, Vaz AJ, Nakamura PM, Da Silva MV, Machado Ade B. Human neurocysticercosis. IgE in cerebrospinal fluid. Arq. Neuropsiquiatr.55(1), 8–11 (1997).
   PubMed Web of Science ®Google Scholar
• Bueno EC, dos Ramos Machado L, Livramento JA, Vaz AJ. Cellular immune response of patients with neurocysticercosis (inflammatory and non-inflammatory phases). Acta Trop.91(2), 205–213 (2004).
   PubMed Web of Science ®Google Scholar
• Chavarria A, Alcocer-Varela J. Is damage in central nervous system due to inflammation? Autoimmun. Rev.3(4), 251–260 (2004).
   PubMed Web of Science ®Google Scholar
• Alvarez JI, Rivera J, Teale JM. Differential release and phagocytosis of tegument glycoconjugates in neurocysticercosis: implications for immune evasion strategies. PLoS Negl. Trop. Dis.2(4), e218 (2008).
   PubMed Web of Science ®Google Scholar
• Terrazas LI. The complex role of pro- and anti-inflammatory cytokines in cysticercosis: immunological lessons from experimental and natural hosts. Curr. Top. Med. Chem.8(5), 383–392 (2008).
   PubMed Web of Science ®Google Scholar
• Cardona AE, Restrepo BI, Jaramillo JM, Teale JM. Development of an animal model for neurocysticercosis: immune response in the central nervous system is characterized by a predominance of γ δ T cells. J. Immunol.162(2), 995–1002 (1999).
   PubMed Web of Science ®Google Scholar
• Cardona AE, Teale JM. γ/δ T cell-deficient mice exhibit reduced disease severity and decreased inflammatory response in the brain in murine neurocysticercosis. J. Immunol.169(6), 3163–3171 (2002).
   PubMed Web of Science ®Google Scholar
• Alvarez JI, Teale JM. Breakdown of the blood brain barrier and blood–cerebrospinal fluid barrier is associated with differential leukocyte migration in distinct compartments of the CNS during the course of murine NCC. J. Neuroimmunol.173(1–2), 45–55 (2006).
   PubMed Web of Science ®Google Scholar
• Alvarez JI, Colegial CH, Castano CA, Trujillo J, Teale JM, Restrepo BI. The human nervous tissue in proximity to granulomatous lesions induced by Taenia solium metacestodes displays an active response. J. Neuroimmunol.127(1–2), 139–144 (2002).
   PubMed Web of Science ®Google Scholar
• Tuckermann JP, Kleiman A, McPherson KG, Reichardt HM. Molecular mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis. Crit. Rev. Clin. Lab. Sci.42(1), 71–104 (2005).
   PubMed Web of Science ®Google Scholar
• Lowenberg M, Stahn C, Hommes DW, Buttgereit F. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids73(9–10), 1025–1029 (2008).
   PubMed Web of Science ®Google Scholar
• Baschant U, Tuckermann J. The role of the glucocorticoid receptor in inflammation and immunity. J. Steroid Biochem. Mol. Biol.120(2–3), 69–75 (2010).
   PubMed Web of Science ®Google Scholar
• Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med.228(2), 111–133 (2003).
   PubMed Web of Science ®Google Scholar
• Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc. Natl Acad. Sci. USA89(21), 9991–9995 (1992).
   PubMed Web of Science ®Google Scholar
• Pitzalis C, Pipitone N, Bajocchi G et al. Corticosteroids inhibit lymphocyte binding to endothelium and intercellular adhesion: an additional mechanism for their anti-inflammatory and immunosuppressive effect. J. Immunology158(10), 5007–5016 (1997).
   PubMed Web of Science ®Google Scholar
• Brewer JA, Kanagawa O, Sleckman BP, Muglia LJ. Thymocyte apoptosis induced by T cell activation is mediated by glucocorticoids in vivo. J. Immunol.169(4), 1837–1843 (2002).
   PubMed Web of Science ®Google Scholar
• Herold MJ, McPherson KG, Reichardt HM. Glucocorticoids in T cell apoptosis and function. Cell. Mol. Life Sci.63(1), 60–72 (2006).
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Brown DE, Brewer JA, Vogt SK, Muglia LJ. Macrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase. Blood109(10), 4313–4319 (2007).
   PubMed Web of Science ®Google Scholar
• Kitajima T, Ariizumi K, Bergstresser PR, Takashima A. A novel mechanism of glucocorticoid-induced immune suppression: the inhibiton of T cell-mediated terminal maturation of a murine dendritic cell line. J. Clin. Invest.98(1), 142–147 (1996).
   PubMed Web of Science ®Google Scholar
• Cumberbatch M, Dearman RJ, Kimber I. Inhibition by dexamethasone of Langerhans cell migration: influence of epidermal cytokine signals. Immunopharmacology41(3), 235–243 (1999).
   PubMed Web of Science ®Google Scholar
• Matyszak MK, Citterio S, Rescigno M, Ricciardi-Castagnoli P. Differential effects of corticosteroids during different stages of dendritic cell maturation. Eur. J. Immunol.30(4), 1233–1242 (2000).
   PubMed Web of Science ®Google Scholar
• Kim KD, Choe YK, Choe IS, Lim JS. Inhibition of glucocorticoid-mediated, caspase-independent dendritic cell death by CD40 activation. J. Leukoc. Biol.69(3), 426–434 (2001).
   PubMed Web of Science ®Google Scholar
• Reichardt HM, Tuckermann JP, Gottlicher M et al. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J.20(24), 7168–7173 (2001).
   PubMed Web of Science ®Google Scholar
• De Bosscher K, Haegeman G. Minireview: latest perspectives on antiinflammatory actions of glucocorticoids. Mol. Endocrinol.23(3), 281–291 (2009).
   PubMed Web of Science ®Google Scholar
• White AC Jr. New developments in the management of neurocysticercosis. J. Infect. Dis.199(9), 1261–1262 (2009).
   PubMed Web of Science ®Google Scholar
• Alvarez JI, Mishra BB, Gundra UM, Mishra PK, Teale JM. Mesocestoides corti intracranial infection as a murine model for neurocysticercosis. Parasitology137(3), 359–372 (2010).
   PubMed Web of Science ®Google Scholar
• Spina-Franca A, Nobrega JP, Livramento JA, Machado LR. Administration of praziquantel in neurocysticercosis. Tropenmed. Parasitol.33(1), 1–4. (1982).
   PubMedGoogle Scholar
• Garcia HH, Pretell EJ, Gilman RH et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N. Engl. J. Med.350(3), 249–258 (2004).
   PubMed Web of Science ®Google Scholar
• Mall RK, Agarwal A, Garg RK, Kar AM, Shukla R. Short course of prednisolone in Indian patients with solitary cysticercus granuloma and new-onset seizures. Epilepsia44(11), 1397–1401 (2003).
   PubMed Web of Science ®Google Scholar
• Garg RK, Potluri N, Kar AM et al. Short course of prednisolone in patients with solitary cysticercus granuloma: a double blind placebo controlled study. J. Infect.53(1), 65–69 (2006).
   PubMed Web of Science ®Google Scholar
• Kishore D, Misra S. Short course of oral prednisolone on disappearance of lesion and seizure recurrence in patients of solitary cysticercal granuloma with single small enhancing CT lesion: an open label randomized prospective study. J. Assoc. Physicians India55, 419–424 (2007).
   PubMedGoogle Scholar
• Prakash S, Garg RK, Kar AM et al. Intravenous methyl prednisolone in patients with solitary cysticercus granuloma: a random evaluation. Seizure15(5), 328–332 (2006).
   PubMed Web of Science ®Google Scholar
• Singhi P, Singhi S. Neurocysticercosis in children. Indian J. Pediatr.76(5), 537–545 (2009).
   PubMed Web of Science ®Google Scholar
• Carpio A, Kelvin EA, Bagiella E et al. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J. Neurol. Neurosurg. Psychiatry79(9), 1050–1055 (2008).
   PubMed Web of Science ®Google Scholar
• Carpio A, Santillan F, Leon P, Flores C, Hauser WA. Is the course of neurocysticercosis modified by treatment with antihelminthic agents? Arch. Intern. Med.155(18), 1982–1988 (1995).
   PubMed Web of Science ®Google Scholar
• Takayanagui OM, Odashima NS. Clinical aspects of neurocysticercosis. Parasitol. Int.55(Suppl.), S111–S115 (2006).
   PubMedGoogle Scholar
• Marquez-Caraveo C, Gongora-Rivera F, Santos Zambrano J, Hernandez R, Soto-Hernandez JL. Pre-treatment with corticosteroids and a single cycle of high dose albendazole for subarachnoidal cysticercosis. J. Neurol. Neurosurg. Psychiatry75(6), 938–939 (2004).
   PubMed Web of Science ®Google Scholar
• Sotelo J. Treatment of brain cysticercosis. Surg. Neurol.48(2), 110–112 (1997).
   PubMedGoogle Scholar
• Sotelo J, Jung H. Pharmacokinetic optimisation of the treatment of neurocysticercosis. Clin. Pharmacokinet.34(6), 503–515 (1998).
   PubMed Web of Science ®Google Scholar
• Agapejev S, Da Silva MD, Ueda AK. Severe forms of neurocysticercosis: treatment with albendazole. Arq. Neuropsiquiatr.54(1), 82–93 (1996).
   PubMed Web of Science ®Google Scholar
• Poeschl P, Janzen A, Schuierer G, Winkler J, Bogdahn U, Steinbrecher A. Calcified neurocysticercosis lesions trigger symptomatic inflammation during antiparasitic therapy. AJNR Am. J. Neuroradiol.27(3), 653–655 (2006).
   PubMed Web of Science ®Google Scholar
• Vazquez ML, Jung H, Sotelo J. Plasma levels of praziquantel decrease when dexamethasone is given simultaneously. Neurology37(9), 1561–1562 (1987).
   PubMed Web of Science ®Google Scholar
• Jung H, Hurtado M, Medina MT, Sanchez M, Sotelo J. Dexamethasone increases plasma levels of albendazole. J. Neurol.237(5), 279–280 (1990).
   PubMed Web of Science ®Google Scholar
• Takayanagui OM, Lanchote VL, Marques MP, Bonato PS. Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulfoxide with dexamethasone. Ther. Drug Monit.19(1), 51–55 (1997).
   PubMed Web of Science ®Google Scholar
• Mitre E, Talaat KR, Sperling MR, Nash TE. Methotrexate as a corticosteroid-sparing agent in complicated neurocysticercosis. Clin. Infect. Dis.44(4), 549–553 (2007).
   PubMed Web of Science ®Google Scholar